ADVERTISEMENT
The deal, unveiled during an Oval Office event with AstraZeneca Chief Executive Officer Pascal Soriot, follows a similar arrangement the administration announced in September with Pfizer. It marks the second major pharmaceutical pricing agreement under the White House’s executive order seeking to reduce medication costs for Medicaid and direct-to-consumer purchases.
ADVERTISEMENT